Company Overview

Guangdong LongFu Pharmaceutical Co., Ltd is a national high-tech enterprise integrating R&D, production and sales of drugs. In 2017, it became a listed company on the NEEQ(stock abbreviation: LongFu Pharmaceutical, stock code: 870859). With the company's product technology accumulation and innovation in the cerebral nervous system, it has won the titles of "National High-tech Enterprise", "Guangdong Cardiovascular and Cerebrovascular Disease Drug Engineering Technology Research Center", "Zhongshan Biomedical Engineering Technology Research Center" and so on.

The company is deeply engaged in the fields of cardiovascular and cerebrovascular, nervous system drugs, etc., and its main product is brain protein hydrolysate (II) for injection, which is the exclusive variety in China and has a strong market competitive advantage. One of the company's core products, "adenosine monophosphate for injection", has been recognised as the first generic drug, and its market advantage is very significant.

In 2012, the company built a high-standard production and operation headquarters in Nanlang South China Modern Traditional Chinese Medicine City, Zhongshan City, covering an area of 40 acres, with a total investment of 150 million yuan, and a design capacity of 50 million bottles of freeze-dried powder injection products per year, and the production workshop has passed the new GMP certification.